Dr. Xudong Hu 胡旭东
Chief Physician, Associate Professor
Department of Thoracic Radiation Oncology I, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiotherapy, chemotherapy, targeted therapy, and immunotherapy for esophageal cancer, lung cancer, breast cancer, and thymic/mediastinal tumors. Uses TOMO, CyberKnife, proton therapy, and stereotactic radiosurgery for early-stage lung cancer. Specializes in comprehensive care and nutritional support for esophageal cancer.
Dr. Hu is a Chief Physician, Associate Professor, and postdoctoral fellow in oncology. Graduated from Suzhou Medical College in 1998, with a master’s degree (2005), PhD (2010), and postdoctoral training (2010–2013). Leads provincial research projects and has published over 10 papers, including 5 SCI-indexed articles as first or corresponding author. Edited two books and received multiple provincial medical science and technology awards.
Professional roles
- Chair, Patient Education Committee, Shandong Clinical Oncology Society
- Vice Chair, Residency Training Committee, Radiation Therapy Branch, Shandong Medical Doctor Association
- Standing Committee Member, Radiation Oncology Branch, Shandong Anti-Cancer Association
- Vice Chair, Tumor MDT Branch, Shandong Geriatric Medical Association
Name order: in Chinese the family name comes first (Hu Xudong). Papers usually list the name as Xudong Hu or Hu X.
Selected publications
36 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Thorac Dis, 2026 (senior author): Subgroup-specific predictive biomarkers in peripheral blood lymphocyte subsets for immune checkpoint inhibitor response in advanced esophageal squamous cell carcinoma: a prospective study. PubMed 41660450
- Front Oncol, 2025 (senior author): Case Report: Genomic insights and personalized treatment in dual primary esophageal squamous cell carcinoma and gastric adenocarcinoma. PubMed 40963872
- Front Immunol, 2024 (senior author): Heterogeneity in peripheral blood immune lymphocyte subsets predicts the response of immunotherapy or chemoradiotherapy in advanced lung cancer: an analysis across different pathological types, treatment modalities and age. PubMed 39483483
- Transl Lung Cancer Res, 2024 (senior author): Heterogeneity of lymphocyte subsets in predicting immune checkpoint inhibitor treatment response in advanced lung cancer: an analysis across different pathological types, therapeutic drugs, and age groups. PubMed 38973958
- J Cardiothorac Surg, 2023 (senior author): The prognostic value of 11(th) Japanese classification and 8(th) AJCC staging systems in Chinese patients with esophageal squamous cell carcinoma. PubMed 37612706
- J Cancer Res Ther, 2022 (senior author): Effectivity of involved-field radiotherapy for recurrent brain metastasis in patients with small-cell lung cancer. PubMed 36204873
- BMC Cancer, 2022 (senior author): Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial. PubMed 35562713
- Dose Response, 2019 (senior author): Use CT Imaging to Predict the Short-Term Outcome of Concurrent Chemoradiotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma. PubMed 31908624
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion